21 / 51
Immunology 2018
J u l y 0 5 - 0 7 , 2 0 1 8
V i e n n a , A u s t r i a
Page 84
Journal of Clinical Immunology and Allergy
ISSN 2471-304X
1 5
t h
I n t e r n a t i o n a l C o n f e r e n c e o n
Immunology
F
HL1 (four and a half LIM domains protein 1), is a cysteine-rich double
Zinc-finger structure protein, highly expresses in skeletal and cardiac
muscles. FHL1 is shown to involve in muscle growth, myoblast differentiation,
sarcomere formation and structural maintenance. The gene and protein of
FHL1 is associated with several diseases, including Emery–Dreifuss muscular
dystrophy, reducing body myopathy, X-linked myopathy characterized by
postural muscle atrophy, and scapuloperoneal myopathy. Recent study further
shows that the anti-FHL1 autoantibody has a potential pathogenic role in
idiopathic inflammatory myopathies (IIMs) patients. Thus, our study aims to
examine whether the anti-FHL1 autoantibody is associated with IIMs patients in
Taiwan. Anti-FHL1 autoantibodies in plasmas from IIM patients are compared
with healthy controls, as well as disease controls from SLE patients via ELISAs
and immunoblot analyses. We found that the anti-FHL1 autoantibody is shown
to be a novel and muscle-specific autoantibody in Taiwan IIMs patients. It may
coexist with other myositis-specific autoantibody. IIM Patients with anti-FHL1
autoantibody have higher disease severity, especially in dysphagia and muscle
weakness.
Dysphagia in idiopathic inflammatory myopathy patients with
anti-FHL1 autoantibody
Ju-Pi Li and Joung-Liang Lan
China Medical University Hospital, Taiwan
Ju-Pi Li et al., Insights Allergy Asthma Bronchitis 2018, Volume: 4
DOI: 10.21767/2471-304X-C1-003
Biography
Ju-Pi Li has completed her PhD from National Tsing Hua
UniversityandPostdoctoralstudiesfromImmunologyResearch
Center, National Health Research Institutes in Taiwan. She is an
Assistant Research Fellowof ChinaMedical University Hospital.
She has published about 20 papers in reputed journals.
d888203@gmail.com